1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Hypertension, Pulmonary in 69 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to study the effect of Rho kinase inhibitor fasudil on the expression endothelin-1 (ET-1) and nitric oxide (NO) in rats with hypoxic pulmonary hypertension (HPH)." | 7.91 | Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension. ( Hong, Z; Li, JX; Li, SY; Sun, XZ; Tian, XY, 2019) |
| "The aim of this study was to investigate the mechanism of fasudil alleviating hypoxic pulmonary hypertension (HPH)." | 7.83 | Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats. ( Fu, EQ; Li, ZC; Liu, ML; Wang, YX; Zhang, B, 2016) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 7.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 7.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 7.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| " In this study, we examined the acute vasodilator effects of fasudil, a Rho-kinase inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension (PH) in rats." | 7.74 | Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. ( Abe, K; Fukumoto, Y; Jiang, BH; Shimokawa, H; Takaki, A; Tawara, S, 2007) |
| "Fasudil was well tolerated; one patient discontinued treatment." | 5.42 | Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. ( Ai, ZS; Gomberg-Maitland, M; He, J; Jiang, R; Jiang, X; Jing, ZC; Liu, D; Wang, L; Yuan, P; Zhao, QH, 2015) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 5.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 5.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction." | 5.32 | Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| "The optimal dose of Fasudil is still controversial in congenital heart disease accompanied with severe pulmonary hypertension (CHD-PAH)." | 5.30 | The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. ( Liu, R; Ruan, H; Yang, X; Zhang, Y, 2019) |
| "This study aims to study the effect of Rho kinase inhibitor fasudil on the expression endothelin-1 (ET-1) and nitric oxide (NO) in rats with hypoxic pulmonary hypertension (HPH)." | 3.91 | Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension. ( Hong, Z; Li, JX; Li, SY; Sun, XZ; Tian, XY, 2019) |
| " The rats were exposed to10% hypoxia for 3 weeks to establish a PAH model, which showed an increase in right ventricle systolic pressure, right ventricular and pulmonary vascular remodeling, and the accelerated senescence and impaired functions in EPCs, accompanied by an increase in Rho-kinase (ROCK) and NOX activities, p-nmMLC20 level, NOX expression and H2O2 content; these phenomena were reversed by fasudil, a selective inhibitor of ROCK." | 3.83 | Non-muscle myosin light chain promotes endothelial progenitor cells senescence and dysfunction in pulmonary hypertensive rats through up-regulation of NADPH oxidase. ( Gong, ZC; Li, T; Liu, B; Liu, WQ; Luo, XJ; Ma, QL; Peng, J; Peng, JJ; Zhang, JJ, 2016) |
| "The aim of this study was to investigate the mechanism of fasudil alleviating hypoxic pulmonary hypertension (HPH)." | 3.83 | Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats. ( Fu, EQ; Li, ZC; Liu, ML; Wang, YX; Zhang, B, 2016) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 3.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The effects of such regimens were investigated on hemodynamics, right ventricle hypertrophy, PDGF and ROCK in experimental monocrotaline (MCT)-induced pulmonary hypertension." | 3.80 | Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension. ( Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Plichta, P, 2014) |
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 3.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 3.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| "This study aimed to determine whether the Rho-kinase-mediated pathway is involved in the pathogenesis of left-to-right shunt-induced pulmonary hypertension and whether fasudil exhibits acute beneficial effects on the hemodynamics of these patients." | 3.75 | Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. ( Li, F; Sun, R; Xia, W; Yuan, S, 2009) |
| " In this study, we examined the acute vasodilator effects of fasudil, a Rho-kinase inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension (PH) in rats." | 3.74 | Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. ( Abe, K; Fukumoto, Y; Jiang, BH; Shimokawa, H; Takaki, A; Tawara, S, 2007) |
| "Eighty COPD patients with pulmonary artery hypertension were selected and divided into two groups: the treatment group and the control group, which had 40 patients respectively." | 2.79 | Influence of Rho kinase inhibitor Fasudil on late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension. ( Liu, J; Liu, P; Sheng, C; Tang, Y; Zeng, Y; Zhang, H, 2014) |
| " Overall, CAR-modified-liposomes of SOD plus fasudil, given every 72 h, was as efficacious as plain drugs, given every 48 h, suggesting that the formulation can reduce the total drug intake, systemic exposures, and dosing frequency." | 1.46 | Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. ( Ahsan, F; Gupta, N; McMurtry, IF; Nozik-Grayck, E; Rashid, J; Stenmark, KR, 2017) |
| "Fasudil was well tolerated; one patient discontinued treatment." | 1.42 | Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. ( Ai, ZS; Gomberg-Maitland, M; He, J; Jiang, R; Jiang, X; Jing, ZC; Liu, D; Wang, L; Yuan, P; Zhao, QH, 2015) |
| "Fasudil was well tolerated in patients with CHD and severe PAH, and significantly reduced PAP and PVR without affecting CI, SAP or SaO2." | 1.42 | Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects. ( Chen, HY; Cui, CS; Meng, LL; Wang, QG; Xiao, JW; Zhang, DZ; Zhang, P; Zhu, XY, 2015) |
| "Fasudil was released in a continuous fashion over 120 h with a cumulative release of 76%." | 1.40 | Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. ( Absar, S; Ahsan, F; Gupta, N; Komatsu, M; Kotamraju, VR; McMurtry, IF; Nahar, K; Nozik-Grayck, E; Oka, M, 2014) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 1.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 1.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| "Pretreatment with fasudil, a Rho kinase inhibitor, blunted the effects of 5-HT infusion." | 1.37 | Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. ( Abman, SH; Delaney, C; Gien, J; Grover, TR; Roe, G, 2011) |
| "Fasudil treatment lowered pulmonary artery systolic pressure, suppressed pulmonary artery smooth muscle cells proliferation, attenuated pulmonary artery medial wall thickening and inhibited right ventricular hypertrophy together with significant suppression of Rho kinase activity but not Rho activity." | 1.34 | Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. ( Li, AW; Li, FH; Sun, RP; Xia, W; Zhao, CF, 2007) |
| "Fasudil 30 mg was intravenously injected over 30 min in 8 patients (all female, mean +/- SD, 41+/-11 years) with PAH." | 1.33 | Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. ( Isaka, N; Ishikura, K; Ito, M; Nakamura, M; Nakano, T; Ota, S; Yamada, N, 2006) |
| "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction." | 1.32 | Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (21.74) | 29.6817 |
| 2010's | 52 (75.36) | 24.3611 |
| 2020's | 2 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D | 1 |
| Yuan, T | 1 |
| Chen, Y | 1 |
| Zhang, H | 2 |
| Niu, Z | 1 |
| Fang, L | 1 |
| Du, G | 1 |
| Abedi, F | 1 |
| Omidkhoda, N | 1 |
| Arasteh, O | 1 |
| Ghavami, V | 1 |
| Hosseinzadeh, H | 1 |
| Jasińska-Stroschein, M | 3 |
| Oszajca, K | 1 |
| Świtlik, W | 1 |
| Ruchwa, J | 1 |
| Orszulak-Michalak, D | 3 |
| Zhang, Y | 2 |
| Wu, S | 1 |
| Rashid, J | 3 |
| Nahar, K | 3 |
| Raut, S | 1 |
| Keshavarz, A | 2 |
| Ahsan, F | 9 |
| Ruan, HY | 1 |
| Zhang, YG | 1 |
| Liu, R | 2 |
| Sun, XZ | 4 |
| Li, SY | 2 |
| Tian, XY | 3 |
| Hong, Z | 1 |
| Li, JX | 1 |
| Li, C | 1 |
| Liu, PP | 1 |
| Tang, DD | 1 |
| Song, R | 1 |
| Zhang, YQ | 1 |
| Lei, S | 1 |
| Wu, SJ | 1 |
| Hanson, SFL | 1 |
| Terry, MH | 1 |
| Moretta, DT | 1 |
| Power, GG | 1 |
| Wilson, SM | 1 |
| Alam, F | 1 |
| Blood, AB | 1 |
| Giri, PC | 1 |
| Zhuang, R | 1 |
| Wu, J | 1 |
| Lin, F | 1 |
| Han, L | 1 |
| Liang, X | 1 |
| Meng, Q | 1 |
| Jiang, Y | 1 |
| Wang, Z | 1 |
| Yue, A | 1 |
| Gu, Y | 1 |
| Fan, H | 1 |
| Zhou, X | 1 |
| Liu, Z | 1 |
| Ruan, H | 1 |
| Yang, X | 1 |
| Alobaida, A | 1 |
| McMurtry, IF | 8 |
| Nozik-Grayck, E | 4 |
| Stenmark, KR | 2 |
| Owczarek, J | 2 |
| Łuczak, A | 1 |
| Jiang, H | 1 |
| Guan, RJ | 1 |
| Wang, HY | 1 |
| Fukumoto, Y | 9 |
| Yamada, N | 2 |
| Matsubara, H | 1 |
| Mizoguchi, M | 1 |
| Uchino, K | 1 |
| Yao, A | 1 |
| Kihara, Y | 1 |
| Kawano, M | 1 |
| Watanabe, H | 2 |
| Takeda, Y | 1 |
| Adachi, T | 1 |
| Osanai, S | 1 |
| Tanabe, N | 2 |
| Inoue, T | 1 |
| Kubo, A | 1 |
| Ota, Y | 1 |
| Fukuda, K | 1 |
| Nakano, T | 2 |
| Shimokawa, H | 10 |
| Bei, Y | 1 |
| Hua-Huy, T | 1 |
| Duong-Quy, S | 1 |
| Nguyen, VH | 1 |
| Chen, W | 1 |
| Nicco, C | 1 |
| Batteux, F | 1 |
| Dinh-Xuan, AT | 1 |
| Miyagawa, K | 1 |
| Emoto, N | 1 |
| Toba, M | 1 |
| Alzoubi, A | 1 |
| O'Neill, KD | 1 |
| Gairhe, S | 1 |
| Matsumoto, Y | 2 |
| Oshima, K | 1 |
| Abe, K | 5 |
| Oka, M | 6 |
| Elias-Al-Mamun, M | 1 |
| Satoh, K | 1 |
| Tanaka, S | 1 |
| Shimizu, T | 1 |
| Nergui, S | 1 |
| Miyata, S | 1 |
| Liu, P | 2 |
| Tang, Y | 1 |
| Sheng, C | 1 |
| Liu, J | 1 |
| Zeng, Y | 1 |
| Plichta, P | 1 |
| Wang, DW | 2 |
| Li, J | 2 |
| Liu, M | 1 |
| Wang, Y | 1 |
| Zheng, L | 1 |
| Zheng, W | 1 |
| Dong, K | 1 |
| Chen, S | 1 |
| Zhang, B | 2 |
| Li, Z | 1 |
| Gupta, N | 6 |
| Ibrahim, HM | 1 |
| Absar, S | 1 |
| Kotamraju, VR | 1 |
| Komatsu, M | 2 |
| Gosal, K | 1 |
| Dunlop, K | 1 |
| Dhaliwal, R | 1 |
| Ivanovska, J | 3 |
| Kantores, C | 3 |
| Desjardins, JF | 1 |
| Connelly, KA | 1 |
| McNamara, PJ | 3 |
| Jain, A | 1 |
| Jankov, RP | 3 |
| Patel, B | 2 |
| Jiang, R | 1 |
| Ai, ZS | 1 |
| Jiang, X | 1 |
| Yuan, P | 1 |
| Liu, D | 1 |
| Zhao, QH | 1 |
| He, J | 1 |
| Wang, L | 1 |
| Gomberg-Maitland, M | 1 |
| Jing, ZC | 1 |
| Xiao, JW | 1 |
| Zhu, XY | 1 |
| Wang, QG | 1 |
| Zhang, DZ | 1 |
| Cui, CS | 1 |
| Zhang, P | 1 |
| Chen, HY | 1 |
| Meng, LL | 1 |
| Zhang, HM | 1 |
| Tang, YJ | 1 |
| Sheng, CF | 1 |
| Liu, JX | 1 |
| Zeng, YJ | 1 |
| Al-Saikhan, FI | 1 |
| Odagiri, K | 1 |
| Wu, QQ | 1 |
| Liu, B | 1 |
| Li, T | 1 |
| Peng, JJ | 1 |
| Zhang, JJ | 1 |
| Liu, WQ | 1 |
| Luo, XJ | 1 |
| Ma, QL | 1 |
| Gong, ZC | 1 |
| Peng, J | 1 |
| Lopez, NC | 1 |
| Ebensperger, G | 1 |
| Herrera, EA | 1 |
| Reyes, RV | 1 |
| Calaf, G | 1 |
| Cabello, G | 1 |
| Moraga, FA | 1 |
| Beñaldo, FA | 1 |
| Diaz, M | 1 |
| Parer, JT | 1 |
| Llanos, AJ | 1 |
| Zychowski, KE | 1 |
| Lucas, SN | 1 |
| Sanchez, B | 1 |
| Herbert, G | 1 |
| Campen, MJ | 1 |
| Wang, YX | 1 |
| Liu, ML | 1 |
| Fu, EQ | 1 |
| Li, ZC | 1 |
| Li, F | 1 |
| Xia, W | 2 |
| Yuan, S | 1 |
| Sun, R | 1 |
| Chen, XY | 1 |
| Dun, JN | 1 |
| Miao, QF | 1 |
| Zhang, YJ | 1 |
| Ziino, AJ | 1 |
| Belcastro, R | 1 |
| Xu, EZ | 2 |
| Lau, M | 1 |
| Tanswell, AK | 1 |
| Fujita, H | 1 |
| Saji, K | 1 |
| Sugimura, K | 1 |
| Demachi, J | 1 |
| Nawata, J | 1 |
| Mouchaers, KT | 1 |
| Schalij, I | 1 |
| de Boer, MA | 1 |
| Postmus, PE | 1 |
| van Hinsbergh, VW | 1 |
| van Nieuw Amerongen, GP | 1 |
| Vonk Noordegraaf, A | 1 |
| van der Laarse, WJ | 1 |
| Dai, ZK | 1 |
| Wu, BN | 1 |
| Chen, IC | 1 |
| Chai, CY | 1 |
| Wu, JR | 1 |
| Chou, SH | 1 |
| Yeh, JL | 1 |
| Chen, IJ | 1 |
| Tan, MS | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| Schwenke, DO | 1 |
| Pearson, JT | 1 |
| Sonobe, T | 1 |
| Ishibashi-Ueda, H | 1 |
| Shimouchi, A | 1 |
| Kangawa, K | 1 |
| Umetani, K | 1 |
| Shirai, M | 1 |
| Yasuda, T | 1 |
| Tada, Y | 1 |
| Tatsumi, K | 1 |
| West, J | 1 |
| Delaney, C | 1 |
| Gien, J | 1 |
| Grover, TR | 1 |
| Roe, G | 1 |
| Abman, SH | 1 |
| Seto, M | 2 |
| Asano, T | 1 |
| Kojonazarov, B | 1 |
| Myrzaakhmatova, A | 1 |
| Sooronbaev, T | 1 |
| Ishizaki, T | 1 |
| Aldashev, A | 1 |
| Yu, YP | 1 |
| Huang, XM | 1 |
| Zhao, YD | 1 |
| Cai, L | 1 |
| Mirza, MK | 1 |
| Huang, X | 1 |
| Geenen, DL | 1 |
| Hofmann, F | 1 |
| Yuan, JX | 1 |
| Zhao, YY | 1 |
| Raja, SG | 1 |
| Gupta, V | 1 |
| Shaik, IH | 1 |
| Mehvar, R | 1 |
| Morikawa, K | 1 |
| Uwatoku, T | 2 |
| Oi, K | 2 |
| Hattori, T | 1 |
| Nakashima, Y | 1 |
| Kaibuchi, K | 2 |
| Sueishi, K | 1 |
| Takeshit, A | 1 |
| Nagaoka, T | 2 |
| Fagan, KA | 1 |
| Gebb, SA | 2 |
| Morris, KG | 3 |
| Suzuki, T | 1 |
| Matoba, T | 1 |
| Ito, A | 1 |
| Tanaka, H | 1 |
| Kishi, T | 1 |
| Hayashidani, S | 1 |
| Takeshita, A | 1 |
| Guilluy, C | 1 |
| Sauzeau, V | 1 |
| Rolli-Derkinderen, M | 1 |
| Guérin, P | 1 |
| Sagan, C | 1 |
| Pacaud, P | 1 |
| Loirand, G | 1 |
| Karoor, V | 1 |
| Homma, N | 2 |
| Ishikura, K | 1 |
| Ito, M | 1 |
| Ota, S | 1 |
| Nakamura, M | 1 |
| Isaka, N | 1 |
| Tawara, S | 4 |
| Hizume, T | 1 |
| Li, FH | 1 |
| Li, AW | 1 |
| Zhao, CF | 1 |
| Sun, RP | 1 |
| Jiang, BH | 1 |
| Takaki, A | 1 |
| Taraseviciene-Stewart, L | 1 |
| Kraskauskas, D | 1 |
| Burns, N | 1 |
| Voelkel, NF | 1 |
8 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension, Pulmonary
| Article | Year |
|---|---|
The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Hemodynamics; Humans; Hypertension, Pulmonary; Protei | 2023 |
Effects of fasudil on pulmonary hypertension in clinical practice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Synergism; Huma | 2017 |
[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Drug Therapy, Combination; Epopros | 2014 |
[Rho-kinase inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Clinical Trials as Topic; Coronary A | 2011 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprosten | 2012 |
Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiovascular System; Disease Models, Anima | 2012 |
[Development of Rho kinase inhibitors for pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Drug Design; Humans; Hypertension, Pulmonary; | 2012 |
Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Humans; Hypertension, Pulmonary; Intracellul | 2007 |
7 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Familial Primary Pulmonary Hypertension; Heart | 2018 |
The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Blood Pressure; Cardiac Catheteriz | 2019 |
Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Double-Blind Method; Female; Hemodynamic | 2013 |
Influence of Rho kinase inhibitor Fasudil on late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Cell Adhesion; Cell Movement; Cell Proliferatio | 2014 |
Influence of Rho kinase inhibitor fasudil on late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Cell Adhesion; Endothelial Progenitor Ce | 2015 |
Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Adult; Aged; Antihyperten | 2010 |
Effects of fasudil in patients with high-altitude pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acclimatization; Altitude Sickness; Humans; Hypertens | 2012 |
54 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension, Pulmonary
| Article | Year |
|---|---|
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertensi | 2022 |
Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Enzyme-Linked Immuno | 2017 |
Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chemistry, Pharmaceutical; Disease Progressi | 2018 |
Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Endothelin-1; Hypert | 2019 |
Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Hypoxia; Interleuki | 2018 |
Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Aerosols; Animals; Animal | 2018 |
Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cell Line; Heart Diseases; Hum | 2018 |
CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Half-Life; Heparitin | 2019 |
The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cholesterol, HDL; Drug Therapy, Combination; | 2013 |
[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Familial Primary Pul | 2013 |
Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bleomycin; Disease Models, Animal; Humans; H | 2013 |
A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Female; Hemodynamics; Humans; Hypertension, Pulmonary | 2013 |
Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Familial Primary Pu | 2014 |
Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium Channel Blockers; Drug Therapy, Comb | 2014 |
Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Becaplermin; Benzamides; Disease Models, Ani | 2014 |
Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blood Pressure; Carotid Arteries | 2014 |
Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Disease Models, Animal | 2014 |
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Animals; Antihypertensive | 2014 |
Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Liposomes; Male; Pe | 2014 |
Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5 | 2015 |
Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Membrane Permeability; Drug Carriers; H | 2014 |
Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Adult; Female; Heart Fai | 2015 |
Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Cardiac Catheterization; Female; H | 2015 |
Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Animals; Bronchoalveolar | 2015 |
Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Female; Heart Defects, Congenital; Hemodynamics; Huma | 2015 |
Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Heart; Hypertension, | 2015 |
Non-muscle myosin light chain promotes endothelial progenitor cells senescence and dysfunction in pulmonary hypertensive rats through up-regulation of NADPH oxidase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cellular Senescence; Endothelial Progenitor | 2016 |
Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude Sickness; Animals; Animals, Newborn; Humans; | 2016 |
Hypoxia-induced pulmonary arterial hypertension augments lung injury and airway reactivity caused by ozone exposure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Air Pollutants; Animals; Bronchial Hyperreactivity; B | 2016 |
Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin I; Animals; Gene Expression; Hypertension | 2016 |
Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterial Pressure; Chemistry, Pharmaceutical | 2017 |
Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Child; Female; Follow-Up Studies; Heart D | 2009 |
Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Cycle; Cell Proliferation; Cells, Cultu | 2009 |
Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Airway Remodeling; Amides; Animals; Animals, Newborn; | 2010 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agent | 2010 |
Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Cyclic GMP; Endothelin-1; Hypert | 2011 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Angiography; Animals; Endothelium, Vas | 2011 |
Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute-Phase Proteins; Animals; Blotting, Western; Bon | 2011 |
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dose-Response Relationship, Drug; Female; Fe | 2011 |
Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/Rho kinase activation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antihypertensive Agents; Cells, Cultured; Cy | 2012 |
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Alkalin | 2013 |
Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dose-Response Relationship, Drug; Endotheliu | 2004 |
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Administration, Oral; Ami | 2005 |
Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Female; Humans; Hypertension, Pulmonary; | 2005 |
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Carrier Proteins; Chronic Disease; C | 2005 |
Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude; Animals; Blood Pressure; Blotting, Western; | 2006 |
Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Blood Pressure; Female; Humans; Hypertension, | 2006 |
Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blotting, Western; Disease Model | 2006 |
[Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Hypoxia; Protein Ki | 2006 |
Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Proliferation; Enzyme Activation; Hyper | 2007 |
Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Blotting, Western; Dose-Resp | 2007 |
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Disease Progression; | 2007 |
Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Interactions; D | 2007 |